Juan Carlos
Montero González
Ikertzailea 2021-(e)tik
Complejo Hospitalario Universitario de Albacete
Albacete, EspañaComplejo Hospitalario Universitario de Albacete -ko ikertzaileekin lankidetzan egindako argitalpenak (24)
2021
-
MZ1 co-operates with trastuzumab in HER2 positive breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1
2020
-
Checkpoint kinase 1 pharmacological inhibition synergizes with dna-damaging agents and overcomes platinum resistance in basal-like breast cancer
International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-14
-
Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer
Cancer Letters, Vol. 491, pp. 50-59
-
Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer
Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 5, pp. 3117-3127
2019
-
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1
-
Screening and preliminary biochemical and biological studies of [RuCl(p-cymene)(N, N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models
ACS Omega, Vol. 4, Núm. 8, pp. 13005-13014
2017
-
Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications
Molecular Oncology, Vol. 11, Núm. 12, pp. 1788-1805
-
Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer
Molecular Cancer Therapeutics, Vol. 16, Núm. 11, pp. 2552-2562
-
Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors
Oncotarget, Vol. 8, Núm. 12, pp. 19478-19490
2016
-
Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node
Oncogene, Vol. 35, Núm. 21, pp. 2756-2765
-
In silico analysis guides selection of BET Inhibitors for triple-negative breast cancer treatment
Molecular Cancer Therapeutics, Vol. 15, Núm. 8, pp. 1823-1833
-
Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies
Oncotarget, Vol. 7, Núm. 29, pp. 45042-45051
-
Targeting the EGF/HER ligand-receptor system in cancer
Current Pharmaceutical Design, Vol. 22, Núm. 39, pp. 5887-5898
2015
-
Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer
Oncotarget, Vol. 6, Núm. 29, pp. 27923-27937
-
Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2
Oncotarget, Vol. 6, Núm. 32, pp. 32856-32867
-
Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors
Oncotarget, Vol. 6, Núm. 31, pp. 31272-31283
2014
-
Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer
Oncogene, Vol. 33, Núm. 2, pp. 148-156
-
Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling
BMC Cancer, Vol. 14, Núm. 1
2012
-
Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: Therapeutic implications
Molecular Cancer Therapeutics, Vol. 11, Núm. 6, pp. 1342-1352
2011
-
Inhibition of Src family kinases and receptor tyrosine kinases by dasatinib: Possible combinations in solid tumors
Clinical Cancer Research, Vol. 17, Núm. 17, pp. 5546-5552